Official_Bellicum_Logo_RGB.jpg
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
March 14, 2023 16:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and...
Official_Bellicum_Logo_RGB.jpg
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
February 16, 2023 07:30 ET | Bellicum Pharmaceuticals, Inc.
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater...
Official_Bellicum_Logo_RGB.jpg
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023 18:43 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023 16:36 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
January 19, 2023 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2022 17:49 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) --  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
August 11, 2022 16:02 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
May 12, 2022 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...